Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo

Fig. 2

Oral administration of R-ketorolac reduces omental engraftment in vivo. Mice were injected i.p. with SKOV3ip-GFP cells and omental engraftment was assessed after 18 h as described in Methods. a Representative images of omenta isolated from animals receiving either placebo or R-ketorolac. b Omental engraftment was quantified by GFP fluorescence and normalized to placebo treated animals within individual experiments. These data represent the combined, normalized GFP fluorescence from three separate experiments with 12 total mice. There was a significant difference between placebo and R-ketorolac treated mice; * indicates p-value ≤0.05 using Student’s t-test

Back to article page